NantOmics Acquires Genos

By Bio-IT World Staff

April 13, 2017 NantOmics today announced its acquisition of Genos, a consumer genomics startup that launched its services last year.

Genos was spun out of Complete Genomics last year. The company offered CLIA-certified sequencing done at 75x on-target coverage, and analyzed with GATK. The angle was that customers would own their data. They could download VCF files, or explore their findings with a custom data visualization and exploration platform—Genos Explorer. Last summer, Genos offered Bio-IT World readers and other beta access groups their exomes for $399.

The company’s exome sequencing offering and network launched in December 2016 and achieved Laboratory Accreditation from the College of American Pathologists (CAP) in February 2017. Through the company’s Impact Network, customers could share their sequencing data with research partners. The initial list included, NantBioScience, NantKwest, Broad Institute, and the Utah Foundation for Biomedical Research.

In a press release on the acquisition, NantOmics says it plans to integrate the Genos technology, technical expertise, and data visualization and research platform into its pan-omic analysis tools, further bolstering the company's industry leading precision medicine service that integrates whole genomic sequencing, transcriptomics, predictive proteomics and quantitative proteomics.

“We are excited to integrate the Genos technology and to welcome Genos employees to the NantOmics team,” stated Patrick Soon-Shiong, M.D., founder and CEO of NantOmics, in a statement. “With the addition of the state-of-the-art discovery and research tools from Genos, NantOmics will enhance its comprehensive diagnostic platform which delivers patient-specific pan-omic information and, ultimately, improves disease diagnosis and treatment.”

"NantOmics is a leader in enabling precision medicine and Genos is excited to join forces with NantOmics to help accelerate the field of precision medicine and precision health," said Mark Blumling, co-founder and CEO of Genos.